POS1153 PRELIMINARY EVALUATION OF THE SAFETY AND ANALGESIC EFFICACY OF THE TRPV1 AGONIST RTX-GRT7039 IN KNEE OSTEOARTHRITIS: A RANDOMISED, DOUBLE-BLIND, EXPLORATORY PHASE II STUDY

• Published in: Annals of the rheumatic diseases Vol. 83; no. Suppl 1; pp. 667 - 668
• Main Authors: Ostenfeld, T., Ivanavicius, S., Stancik, R., Conaghan, P. G.
• Format: Journal Article
• Language: English
• Published: Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2024; Elsevier B.V; Elsevier Limited
• Subjects: Agonists; Analgesia; Analgesics; Arthralgia; Arthritis; Capsaicin receptors; Clinical Trial; Euphorbia resinifera; Injection; Knee; Osteoarthritis; Pain; Pain perception; Patients; Placebos; Resiniferatoxin; Rhinopharyngitis; Ropivacaine; Safety; Scientific Abstracts; Transient receptor potential proteins; Clinical Trial; Pain

Background:RTX-GRT7039 (resiniferatoxin; RTX), is a potent and selective agonist of the transient receptor potential vanilloid 1 (TRPV1) being developed for treatment of pain related to knee osteoarthritis (KOA). RTX-mediated activation of TRPV1-expressing neurones is followed by reversible defuncti...